Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Gabapentin enacarbil in restless legs syndrome.

Merlino G, Serafini A, Lorenzut S, Sommaro M, Gigli GL, Valente M.

Drugs Today (Barc). 2010 Jan;46(1):3-11. doi: 10.1358/dot.2010.46.1.1424766. Review.

PMID:
20200691
2.

Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.

Merlino G, Serafini A, Young JJ, Robiony F, Gigli GL, Valente M.

Curr Opin Investig Drugs. 2009 Jan;10(1):91-102.

PMID:
19127491
3.

Gabapentin enacarbil for treatment of restless legs syndrome in adults.

Hayes WJ, Lemon MD, Farver DK.

Ann Pharmacother. 2012 Feb;46(2):229-39. doi: 10.1345/aph.1Q578. Epub 2012 Jan 31. Review.

PMID:
22298601
4.

Gabapentin enacarbil for the treatment of restless legs syndrome (RLS).

Burke RA, Faulkner MA.

Expert Opin Pharmacother. 2011 Dec;12(18):2905-14. doi: 10.1517/14656566.2011.635645. Epub 2011 Nov 14. Review.

PMID:
22077768
5.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.

Clin Ther. 2009 Aug;31(8):1776-86. doi: 10.1016/j.clinthera.2009.07.026.

PMID:
19808136
6.

Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients.

Inoue Y, Uchimura N, Kuroda K, Hirata K, Hattori N.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):251-7. doi: 10.1016/j.pnpbp.2011.10.009. Epub 2011 Oct 19.

PMID:
22036917
7.

Gabapentin Enacarbil: A Review in Restless Legs Syndrome.

Kim ES, Deeks ED.

Drugs. 2016 May;76(8):879-87. doi: 10.1007/s40265-016-0584-1. Review.

PMID:
27146056
8.

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial.

Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP045 Study Group..

Clin Neuropharmacol. 2009 Nov-Dec;32(6):311-20. doi: 10.1097/WNF.0b013e3181b3ab16.

PMID:
19667976
9.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC.

Clin Ther. 2012 Jan;34(1):201-13. doi: 10.1016/j.clinthera.2011.12.004. Epub 2011 Dec 28.

PMID:
22206794
10.

Gabapentin enacarbil: in patients with restless legs syndrome.

Scott LJ.

CNS Drugs. 2012 Dec;26(12):1073-83. doi: 10.1007/s40263-012-0020-3. Review. Erratum in: CNS Drugs. 2013 Feb;27(2):163-4. CNS Drugs. 2013 Jan;27(1):81.

PMID:
23179641
11.

Gabapentin encarbil (Horizant) for restless leg syndrome.

[No authors listed]

Med Lett Drugs Ther. 2011 Sep 5;53(1372):70-1.

PMID:
21897349
12.

A 52-week study of gabapentin enacarbil in restless legs syndrome.

Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D.

Clin Neuropharmacol. 2011 Jan-Feb;34(1):8-16. doi: 10.1097/WNF.0b013e3182087d48.

PMID:
21242741
13.

Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.

Imamura S, Kushida C.

Expert Opin Pharmacother. 2010 Aug;11(11):1925-32. doi: 10.1517/14656566.2010.494598. Review.

PMID:
20629607
14.

[Pharmacological and clinical profile of gabapentin enacarbil: a novel drug for the treatment of restless legs syndrome].

Kakimoto S, Ozawa T, Igarashi K, Tokuno T, Kaku S, Seki N.

Nihon Yakurigaku Zasshi. 2012 Aug;140(2):85-92. Review. Japanese. No abstract available.

PMID:
22878573
15.

Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.

VanMeter SA, Kavanagh ST, Warren S, Barrett RW.

CNS Drugs. 2012 Sep 1;26(9):773-80. doi: 10.2165/11634870-000000000-00000.

PMID:
22849331
16.

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.

Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE.

Mov Disord. 2011 Sep;26(11):2065-72. doi: 10.1002/mds.23771. Epub 2011 May 24.

PMID:
21611981
17.

Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC.

J Clin Pharmacol. 2013 Jan;53(1):29-40. doi: 10.1177/0091270012439209. Epub 2013 Jan 24.

PMID:
23400741
18.

A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, Tovera J, Hurt J, Bonzo D, Lassauzet ML, Vu A, Cundy KC.

Clin Neuropharmacol. 2012 Jul-Aug;35(4):165-73. doi: 10.1097/WNF.0b013e318259eac8.

PMID:
22664749
19.

Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.

Chen D, Lal R, Zomorodi K, Atluri H, Ho J, Luo W, Tovera J, Bonzo D, Cundy K.

Clin Ther. 2012 Feb;34(2):351-362.e3. doi: 10.1016/j.clinthera.2012.01.002.

PMID:
22325733
20.

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study.

Bogan RK, Bornemann MA, Kushida CA, TrĂ¢n PV, Barrett RW; XP060 Study Group..

Mayo Clin Proc. 2010 Jun;85(6):512-21. doi: 10.4065/mcp.2009.0700. Erratum in: Mayo Clin Proc. 2010 Jul;85(7):693-4.

Supplemental Content

Support Center